FDA Brief

Warning letters Biologics

FDA warning letter to

Signature Biologics, LLC

High riskIssued Sep 18, 2023Posted Sep 29, 2023Division of Biological Products Operations II

FDA cited Signature Biologics for unapproved, unlicensed Signature Cord and serious sterile manufacturing failures.

What happened

FDA inspected Signature Biologics from December 1 to December 16, 2021, and documented manufacture of Signature Cord™, a human umbilical cord-derived product for use in other patients that was intended for injection and purported to be sterile. FDA found the product failed the minimal manipulation criterion and was marketed without an approved biologics license or an investigational new drug application. FDA also found significant deviations from current good manufacturing practice (CGMP), including aseptic process validation that did not represent the largest commercial batch, inadequate environmental monitoring, no endotoxin release testing, no process validation, no cleaning validation, and a two-year expiration date without supporting data.

What FDA found

  1. The company marketed Signature Cord without an approved biologics license or an investigational new drug application, which FDA requires to lawfully market or study the product in humans.

    42 U.S.C. 262(a); 21 U.S.C. 355(i); 21 CFR Part 312
  2. The company validated its sterile filling process with test batches smaller than its largest commercial batches.

    21 CFR 211.113(b)
  3. Environmental monitoring in aseptic areas was inadequate, including no viable air monitoring with each production run and allowed high microbe counts.

    21 CFR 211.42(c)(10)(iv)
  4. The company did not test each batch for endotoxin even though the product was represented as pyrogen-free.

    21 CFR 211.167(a)
  5. The manufacturing process was not validated, cleaning and disinfection of biological safety cabinets and cleanrooms was not validated, and finished-product testing was limited to sterility.

    21 CFR 211.100(a); 21 CFR 211.42(c)(10)(v); 21 CFR 211.160(b)
  6. The company assigned a two-year expiration date without stability data to support it.

    21 CFR 211.166(a)

What FDA wants

FDA asks the company to respond in writing within 15 working days from receipt with specific steps and documentation to correct the violations and prevent recurrence. The response must also address the lack of an approved license or IND and the impact on distributed product and inventory disposition.

Who should pay attention

  • health care professionals and facilities that received Signature Cord
  • companies marketing human cell or tissue products
  • sterile biologic manufacturers and their suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Beaute Bounty

    FDA warns Beaute Bounty that its stem cell and placenta products are unapproved drugs and unlicensed biologics.

    High risk
  2. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  3. Blue Horizon International, LLC

    FDA warned Blue Horizon International over unapproved stem cell and exosome biologics marketed for serious diseases without a license.

    High risk
  4. Dynamic Stem Cell Therapy

    FDA warned Dynamic Stem Cell Therapy that its umbilical cord-derived stem cell product is an unapproved, unlicensed, misbranded biological drug.

    High risk